^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug Class: | EGFR inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
Published date:
09/12/2023
Excerpt:
In this retrospective observational study, we enrolled patients with resected stage III adenocarcinoma with EGFR mutations between January 2011 and December 2021....Perioperative EGFR-TKIs led to longer progression-free survival (PFS) than chemotherapy (38.6 versus 14.2 months; p = 0.019).
DOI:
10.1186/s12885-023-11342-y
Source:
Title:
Clinical Features and Outcome Evaluation of Patients with Non-small-Cell Lung Cancer: A Single Center Study
Published date:
08/08/2023
Excerpt:
The clinical features of NSCLC were male sex, non-smokers, mostly elderly, adenocarcinoma pathology, and diagnosed at advanced metastatic stage. Most subjects had EGFR mutation and underwent anti-EGFR treatment. The evaluation after the first 6 months, mostly were in favorable response....
Source:
Title:
Concurrent chemotherapy and first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first-line treatment in advanced lung adenocarcinoma harboring an EGFR mutation
Published date:
06/28/2021
Excerpt:
A total of 30 patients with advanced lung adenocarcinoma and activating EGFR mutations concurrently received an EGFR-TKI and platinum-based doublet chemotherapy with or without bevacizumab….Of the 28 patients who had measurable lesions, the objective response rate and disease control rate were 71.4% and 96.4%, respectively (one patient achieved complete remission, 19 patients had a partial response and seven patients had stable disease).
Secondary therapy:
Chemotherapy
DOI:
10.1111/1759-7714.14057
Source:
Title:
MA12.08 - Chemotherapy plus EGFR TKIs or Bevacizumab versus Chemotherapy Alone in SCLC-Transformed EGFR-Mutant Lung Adenocarcinoma
Published date:
01/12/2021
Excerpt:
We divided all the patients into two groups according to different subsequent regimens just after SCLC transformation. There were 12 in the etoposide/cisplatin or irinotecan/cisplatin chemotherapy group (EP/IP group) and 9 in the chemotherapy plus bevacizumab or EGFR-TKIs group (Combo group). The ORR was significantly higher in the Combo group than the EP/IP group (50% vs 25%, P=0.002)....Chemotherapy plus EGFR TKIs or bevacizumab could provide better efficacy than chemotherapy alone for SCLC-transformed EGFR-mutant patients with advanced lung adenocarcinoma.
Secondary therapy:
Chemotherapy
Source:
Title:
Downregulation of caveolin-1 increased EGFR-TKIs sensitivity in lung adenocarcinoma cell line with EGFR mutation
Excerpt:
CONTRADICTING EVIDENCE:...results suggest that Cav-1 may be a predictor of the poor efficacy of EGFR-TKIs treatment in lung adenocarcinoma with EGFR mutations.
DOI:
10.1016/j.bbrc.2017.11.075